依达拉奉联合丁苯酞治疗急性缺血性脑卒中的效果探讨

Efficacy of Edaravone Combined with Butylphthalide in the Treatment of Acute Ischemic Stroke

目的探讨依达拉奉联合丁苯酞治疗急性缺血性脑卒中的临床效果。方法选择2018年3月-2019年5月该院收治的缺血性卒中急性期患者80例,按照随机数字表法分为两组,各40例。对照组应用依达拉奉,观察组在对照组基础上联合应用丁苯酞,连续治疗2周为1个疗程。对所有患者住院时间进行统计,并比较干预后2周机体炎症因子水平及机体抗氧化能力情况;比较干预后2周两组神经功能及生活质量评分变化;统计两组住院时间。结果干预后2周观察组hs-CRP及IL-6水平分别为(7.2±0.5)mg/L和(0.4±0.1)ηg/L均显著低于对照组的(18.5±1.2)mg/L和(1.1±0.2)ηg/L(t=26.027,19.799,P<0.05),干预后2周观察组MDA水平为(3.8±0.2)mol/L低于对照组的(6.6±0.4)mol/L(t=39.598,P<0.05),SOD水平为(0.7±0.2)U/L高于对照组的(0.4±0.1)U/L(t=8.485,P<0.05),干预后2周观察组神经功能及生活质量评分为(86.1±5.5)分和(85.6±6.9)分,均显著高于对照组的(63.6±3.2)分和(73.1±4.6)分(t=22.363、9.533,P<0.05),观察组住院时间为(16.3±2.3)d,对照组住院时间为(26.9±5.6)d,观察组住院时间显著短于对照组(t=11.074,P=0.000<0.05)。结论针对急性缺血性脑卒中患者在应用依达拉奉基础上使用丁苯酞,可有效降低机体炎症反应,提高抗氧化能力,改善神经功能及生活质量,缩短住院时间。

Objective To explore the clinical effect of edaravone combined with butylphthalide in the treatment of acute ischemic stroke.Methods Ischemic stroke treated in the hospital from March 2018 to May 2019,80 patients in the acute phase were divided into two groups according to the random number table method,each with 40 patients.The control group was treated with edaravone,and the observation group was combined with butylphthalide on the basis of the control group.Continuous treatment for 2 weeks was 1 course.The length of hospitalization of all patients was counted,and the levels of inflammatory factors and the body's antioxidant capacity were compared 2 weeks after the intervention;the changes in neurological function and quality of life scores of the two groups were compared 2 weeks after the intervention;Results The levels of hs-CRP and IL-6 in the observation group 2 weeks after the intervention were(7.2±0.5)mg/L and(0.4±0.1)ηg/L,which were significantly lower than those in the control group(18.5±1.2)mg/L and(1.1±0.2)ηg/L(t=26.027,19.799,P<0.05),the MDA level in the observation group at 2 weeks after the intervention was(3.8±0.2)mol/L lower than the control group(6.6±0.4)mol/L(t=39.598,P<0.05),SOD level was(0.7±0.2)U/L was higher than that of the control group(0.4±0.1)U/L(t=8.485,P<0.05),and the neurological function of the group was observed 2 weeks after the intervention And the quality of life scores were(86.1±5.5)points and(85.6±6.9)points,which were significantly higher than the(63.6±3.2)points and(73.1±4.6)points of the control group(t=22.363,9.533,P<0.05).The length of stay in the observation group was(16.3±2.3)d,and the length of stay in the control group was(26.9±5.6)d.The length of stay in the observation group was significantly shorter than that of the control group(t=11.074,P=0.000<0.05).Conclusion The use of butylphthalide on the basis of edaravone in patients with acute ischemic stroke can effectively reduce the body's inflammatory response,improve the antioxidant capacity,improve neurological function and quality of life,and shorten the length of hospital stay.